Ethambutol Remains Part of TB Treatment Guidelines
Ethambutol is still included in current tuberculosis treatment guidelines, though its use has become more selective based on risk stratification for drug resistance. The drug has not been removed from TB treatment protocols; rather, modern guidelines allow for its omission in specific low-risk populations.
Current Guideline Recommendations for Drug-Susceptible TB
Standard First-Line Regimen
The recommended treatment for drug-susceptible pulmonary tuberculosis consists of a four-drug initial phase for 2 months: rifampicin, isoniazid, pyrazinamide, and ethambutol (HRZE), followed by rifampicin and isoniazid for 4 months 1. This six-month regimen remains the global standard for treating drug-susceptible TB 1.
When Ethambutol Can Be Omitted
Ethambutol may be omitted in patients at low risk of isoniazid resistance, specifically:
- Previously untreated patients who are HIV-negative 1
- Patients known to have fully drug-susceptible organisms 1
- Patients not in contact with known drug-resistant TB cases 1
The rationale for including ethambutol is primarily to prevent emergence of rifampicin resistance in cases of unrecognized isoniazid resistance 1, 2. In populations where isoniazid resistance is uncommon (<2% in previously untreated patients), the fourth drug becomes less critical once susceptibility is confirmed 1.
High-Risk Populations Requiring Ethambutol
Ethambutol should be included as the fourth drug in the initial phase for patients at increased risk of drug resistance 1:
- Ethnic minority groups (particularly those of Indian subcontinent and Black African origin, where isoniazid resistance occurs in 4-6%) 1
- HIV-positive individuals (fourfold increased risk of drug resistance) 1
- Patients with previous TB treatment history 1
- Contacts of known drug-resistant cases 1
Dosing Recommendations
For drug-susceptible TB, ethambutol is dosed at 15 mg/kg daily 1. For drug-resistant TB, higher doses of 25 mg/kg are recommended to maximize efficacy, though this increases the risk of ocular toxicity 1.
Role in Drug-Resistant TB
For multidrug-resistant TB (MDR-TB), ethambutol should only be included when more effective drugs cannot be assembled to achieve five effective drugs in the regimen 1. The 2019 ATS/CDC/ERS/IDSA guidelines give this a conditional recommendation with very low certainty of evidence, reflecting that ethambutol is a weaker agent compared to newer drugs like fluoroquinolones, linezolid, and bedaquiline 1.
Recent Evidence on Ethambutol-Free Regimens
A 2022 French trial (FAST-TB) demonstrated that in settings with low isoniazid resistance prevalence, a three-drug regimen (isoniazid, rifampicin, pyrazinamide) based on rapid molecular detection of isoniazid susceptibility was noninferior to the standard four-drug regimen 2. This supports the selective omission of ethambutol when resistance can be rapidly excluded.
However, attempts to shorten treatment duration to 4 months using fluoroquinolone-containing regimens (replacing ethambutol with moxifloxacin or gatifloxacin) have shown increased relapse rates compared to standard 6-month therapy, and these shortened regimens are not currently recommended 3.
Safety Monitoring
All patients receiving ethambutol require monthly monitoring for ocular toxicity, particularly visual impairment, decreased visual acuity, scotomata, and color blindness 1. These effects are dose-dependent and generally reversible if detected early and the drug is discontinued 1. The risk is higher with the 25 mg/kg dosing used in MDR-TB treatment 1.
Clinical Pitfalls to Avoid
- Do not omit ethambutol in children with "adult-type" TB (upper lobe infiltration, cavitation) or when drug resistance is suspected, despite concerns about monitoring visual acuity 1
- Do not continue ethambutol beyond 2 months in the initial phase for drug-susceptible TB once susceptibility is confirmed 1
- Do not use ethambutol as monotherapy or dual therapy—it must always be part of a multi-drug regimen 4
- Do not rechallenge with ethambutol after optic neuritis develops, unlike linezolid which may be safely reintroduced 1